THThekra F. Hasan

Thekra F. Hasan

*This is an algorithmically generated author record based on publicly available information.

Thekra F. Hasan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Theranostic potential of ultrasound-guided sonodynamic therapy for cancer: a systematic review of preclinical studies

    by Herlina Uinarni, Munojat Ismailova, Thekra F. Hasan, Majid S. Jabir, Wesam R. Kadhum

    Ultrasound-guided sonodynamic therapy (US-guided SDT) is an emerging theranostic approach that combines noninvasive tumor treatment with real-time imaging. By activating sonosensitizers through focused US to produce reactive oxygen species (ROS), SDT enables targeted tumor ablation with minimal systemic toxicity. This systematic review summarizes preclinical advancements in US-guided SDT from 2015 to 2025. Comprehensive searches across PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar identified 24 eligible studies. Extracted data included nanoplatform characteristics, parameters, imaging modalities, therapeutic outcomes, and translational potential. Across studies, US served both as an imaging and activation modality, enabling simultaneous diagnosis and therapy. Nanoparticle-based sonosensitizers enhanced ROS yield, tumor selectivity, and imaging contrast. Most studies reported significant tumor inhibition (> 70%), precise targeting, and favorable biosafety. Multifunctional nanoplatforms integrating oxygen generation, immunomodulation, or chemotherapeutic co-delivery further improved efficacy. US-guided SDT exhibits robust preclinical evidence as a dual-function imaging and treatment platform. However, lack of standardized US parameters, limited long-term safety data, and reliance on subcutaneous tumor models hinder clinical translation. Future studies should emphasize standardized dosimetry, advanced tumor models, and comprehensive biosafety evaluation to advance this promising theranostic modality toward clinical application. Graphical Abstract


  • CXCR4/CXCL12 blockade therapy; a new horizon in TNBC therapy

    by Abdulrahman Qais Khaleel, Farag M. A. Altalbawy, Majid S. Jabir, Thikra F.HAsan, Vicky Jain, Vikrant Abbot, Prashant Nakash, M. Ravi Kumar, Yasser Fakri Mustafa, Mohammed Abed Jawad

    The only subtype of breast cancer (BC) without specific therapy is triple-negative breast cancer (TNBC), which represents 15–20% of incidence cases of BC. TNBC encompasses transformed and nonmalignant cells, including cancer-associated fibroblasts (CAF), endothelial vasculature, and tumor-infiltrating cells. These nonmalignant cells, soluble factors (e.g., cytokines), and the extracellular matrix (ECM) form the tumor microenvironment (TME). The TME is made up of these nonmalignant cells, ECM, and soluble components, including cytokines. Direct cell-to-cell contact and soluble substances like cytokines (e.g., chemokines) may facilitate interaction between cancer cells and the surrounding TME. Through growth-promoting cytokines, TME not only enables the development of cancer but also confers therapy resistance. New treatment targets will probably be suggested by comprehending the processes behind tumor development and progression as well as the functions of chemokines in TNBC. In this light, several investigations have shown the pivotal function of the C-X-C motif chemokine ligand 12 (CXCL12 or SDF-1) axis and chemokine receptor type 4 (CXCR4) in the pathophysiology of TNBC. This review provides an overview of the CXCR4/CXCL12 axis’ function in TNBC development, metastasis, angiogenesis, and treatment resistance. A synopsis of current literature on targeting the CXCR4/CXCL12 axis for treating and managing TNBC has also been provided.


  • Advancements in radiobiology techniques and applications for personalized radiation therapy in nuclear medicine

    by Yibo He, Maher Ali Rusho, Soumya V. Menon, Mandeep Kaur, Majid S. Jabir, Sabrean Farhan Jawad, Thikra F. Hasan, Mazin A. A. Najm, Mohammed Abed Jawad, Ali J. Khelief